Wendy Guy

Wendy Guy, listed as senior executive, appears in our data through filings on Processa Pharmaceuticals, Inc. shares, published by SEC (Form 4). We count 10 filings; the first trade dates from 5 August 2021 and the latest from 30 April 2026.

Purchases make up the whole of the open-market record (3 purchases, €12k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants and 5 option exercises. Since January 2026: 3 purchases and no sales on the market.

A typical purchase (the median) is worth €4,009. On 3 out of 3 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 1 May 2026, reports an open-market purchase of €4,009 in Processa Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.